Research in Social and Administrative Pharmacy
Volume 1, Issue 1 , Pages 126-133 , March 2005

The role of hospital and community pharmacists in pharmacovigilance

  • A.C. van Grootheest, M.D., Ph.D.

      Affiliations

    • Netherlands Pharmacovigilance Centre Lareb, Hertogenbosch, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 73 6469700.
    • ,
  • L.T.W. de Jong-van den Berg, Pharm.D., Ph.D.

      Affiliations

    • Department of Social Pharmacy and Pharmacoepidemiology, GUIDE, Groningen, The Netherlands

References 

  1. WHO . The Importance of Pharmacovigilance, Safety Monitoring of Medical Products. Geneva: WHO; 2002;
  2. van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13:457–464
  3. Clause S, Fudin J, Mergner A, et al. Prescribing privileges among pharmacists in Veterans Affairs medical centres. Am J Health Syst Pharm. 2001;58:1143–1145
  4. Strom BL, Hennessy S. Pharmacist care and clinical outcomes for patients with reactive airways disease. JAMA. 2002;288:1642–1643
  5. van Mil F, McElnay J, de Jong-van den Berg LTW, Tromp DFJ. The challenges of defining pharmaceutical care on an international level. Int J Pharm Pract. 1999;7:202–208
  6. Beard K. Introduction. In:  Strom BL editors. Adverse Drug Reactions. London: Pharmaceutical Press; 2001;
  7. Poston J, Parish P. The pharmacists. In:  Inman WHW editors. Monitoring for Drug Safety. Lancaster: MTP Press; 1986;
  8. Major E. The yellow card scheme and the role of pharmacists as reporters. Pharm J. 2002;269:25–26
  9. Olsson S. National Pharmacovigilance Systems—Country Profiles and Overview. 2nd ed.. Uppsala: Uppsala Monitoring Centre; 1999;
  10. Kelly B. Pharmacovigilance: more a responsibility than a role. Aust Pharm. 2001;20:128
  11. Griffin JP. Survey of the spontaneous adverse drug reactions reporting schemes in fifteen countries. Br J Clin Pharmacol. 1986;12:243–247
  12. Fincham JE. Adverse drug reaction reporting and pharmacists. J Clin Pharm Ther. 1989;14:79–81
  13. Lindquist M, Edwards IR. Adverse drug reactions reporting in Europe: some problems of comparison. Int J Risk Safety Med. 1993;4:35–46
  14. Roberts PI, Wolfson DJ, Booth TG. The role of pharmacists in adverse drug reaction reporting. Drug Saf. 1994;11:7–11
  15. Leape LL, Cullen DJ, Dempsey Clapp M, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282:267–270
  16. Wistanley PA, Irvin LE, Smith JC, Orme ML'E, Breckenridge AM. Adverse drug reactions: a hospital pharmacy-based reporting scheme. Br J Clin Pharmacol. 1989;28:113–116
  17. Ahmad SR, Freiman JP, Graham DJ, Nelson RC. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf. 1996;5:1–7
  18. Moss RL, Garnett WR, Steiner KC. Physician attitudes toward pharmacists counseling patients on adverse drug reactions. Am J Hosp Pharm. 1980;37:243–247
  19. Pouyanne P, Haramburu F, Imbs JL, Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ. 2000;320:1036
  20. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205
  21. Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf. 2002;11:65–72
  22. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patient. BMJ. 2004;329:15–19
  23. Anonymous . Top-priority actions for preventing adverse drug events in hospitals. Recommendations of an expert panel. Am J Health Syst Pharm. 1996;53:747–751
  24. van de Bemt PMLA. Drug safety in hospitalised patients [thesis]. Rijksuniversiteit Groningen. Groningen; 2002.
  25. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf. 2000;22:161–168
  26. Emerson AE, Martin RM, Tomlin M, Mann RD. Prospective cohort study of adverse events monitored by hospital pharmacists. Pharmacoepidemiol Drug Saf. 2001;10:95–103
  27. Lee A, Bateman DN, Edwards C, Smith JM, Rawlins MD. Reporting of adverse drug reactions by hospital pharmacists: pilot schema. BMJ. 1997;315:520–523
  28. Thürmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. 2001;24:961–968
  29. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In:  Strom WHW editors. Pharmacoepidemiology. Chichester, UK: John Wiley and Sons; 2000;
  30. Sills JM, Tanner AM, Milstien JB. Food and Drug Administration monitoring of adverse drug reactions. Am J Hosp Pharm. 1986;43:2764–2770
  31. Accreditation Manual for Hospitals 1993. Oakbrook Terrace, Ill: Joint Commission on Accreditation of Healthcare Organizations; 1993;
  32. Strom BL. Pharmacoepidemiology: response to the challenge. Pharmacoepidemiol Drug Saf. 1995;4:11–14
  33. CSHP . Standards of Practice. Canadian Society of Hospital Pharmacists. 1990;
  34. Hardman C, Lloyd B. Adverse drug reaction monitoring by ward pharmacists. J Clin Hosp Pharm. 1982;7:71–73
  35. Irvin LE, Grimmer SFM, Smith JC. Adverse drug reaction reporting. Br J Pharm Pract. 1987;9:316–321
  36. van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:205–210
  37. van Grootheest AC, Mes K, de Jong-van den Berg LTW. Attitudes of community pharmacists in the Netherlands towards ADR reporting. Int J Pharm Pract. 2002;10:267–272
  38. Green CF, Mottram DR, Raval D, Proudlove C, Randall C. Community pharmacists' attitude to adverse drug reaction reporting. Int J Pharm Pract. 1999;7:92–99
  39. Debesa F, Giménez G, Firgueras A, et al. Spontaneous reporting of adverse drug reactions in Cuba: integrating continuous education, training and research in a network approach. Br J Clin Pharmacol. 2002;54:333–336
  40. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy; a feasible option?. Pharmacoepidemiol Drug Saf. 1999;8:479–491
  41. Sinclair HK, Bond CM, Hannaford PC. Long term follow-up studies of users of nonrescription medicines purchased from community pharmacies. Drug Saf. 2001;24:929–939
  42. Wade OL. Adverse Reactions to Drugs. London: Heinemann Medical Books; 1970;

PII: S1551-7411(04)00010-5

doi: 10.1016/j.sapharm.2004.12.009

Research in Social and Administrative Pharmacy
Volume 1, Issue 1 , Pages 126-133 , March 2005

Article Tools